Show simple item record

dc.contributor.author Allen, KD
dc.contributor.author Adams, SB
dc.contributor.author Setton, LA
dc.coverage.spatial United States
dc.date.accessioned 2011-04-15T16:46:37Z
dc.date.issued 2010-02
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/19943805
dc.identifier.citation Tissue Eng Part B Rev, 2010, 16 (1), pp. 81 - 92
dc.identifier.uri http://hdl.handle.net/10161/3360
dc.description.abstract Osteoarthritis (OA) is a degenerative joint disease that can result in joint pain, loss of joint function, and deleterious effects on activity levels and lifestyle habits. Current therapies for OA are largely aimed at symptomatic relief and may have limited effects on the underlying cascade of joint degradation. Local drug delivery strategies may provide for the development of more successful OA treatment outcomes that have potential to reduce local joint inflammation, reduce joint destruction, offer pain relief, and restore patient activity levels and joint function. As increasing interest turns toward intra-articular drug delivery routes, parallel interest has emerged in evaluating drug biodistribution, safety, and efficacy in preclinical models. Rodent models provide major advantages for the development of drug delivery strategies, chiefly because of lower cost, successful replication of human OA-like characteristics, rapid disease development, and small joint volumes that enable use of lower total drug amounts during protocol development. These models, however, also offer the potential to investigate the therapeutic effects of local drug therapy on animal behavior, including pain sensitivity thresholds and locomotion characteristics. Herein, we describe a translational paradigm for the evaluation of an intra-articular drug delivery strategy in a rat OA model. This model, a rat interleukin-1beta overexpression model, offers the ability to evaluate anti-interleukin-1 therapeutics for drug biodistribution, activity, and safety as well as the therapeutic relief of disease symptoms. Once the action against interleukin-1 is confirmed in vivo, the newly developed anti-inflammatory drug can be evaluated for evidence of disease-modifying effects in more complex preclinical models.
dc.format.extent 81 - 92
dc.language eng
dc.language.iso en_US en_US
dc.relation.ispartof Tissue Eng Part B Rev
dc.relation.isversionof 10.1089/ten.teb.2009.0447
dc.subject Animals
dc.subject Disease Models, Animal
dc.subject Drug Delivery Systems
dc.subject Evaluation Studies as Topic
dc.subject Injections, Intra-Articular
dc.subject Osteoarthritis
dc.subject Rats
dc.subject Tissue Distribution
dc.title Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model.
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-2-0 en_US
duke.description.endpage 92 en_US
duke.description.issue 1 en_US
duke.description.startpage 81 en_US
duke.description.volume 16 en_US
dc.relation.journal Tissue Engineering Part B-Reviews en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/19943805
pubs.issue 1
pubs.organisational-group /Duke
pubs.organisational-group /Duke/Institutes and Provost's Academic Units
pubs.organisational-group /Duke/Institutes and Provost's Academic Units/University Institutes and Centers
pubs.organisational-group /Duke/Institutes and Provost's Academic Units/University Institutes and Centers/Duke Institute for Brain Sciences
pubs.organisational-group /Duke/Pratt School of Engineering
pubs.organisational-group /Duke/Pratt School of Engineering/Biomedical Engineering
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Orthopaedics
pubs.publication-status Published
pubs.volume 16
dc.identifier.eissn 1937-3376

Files in this item

This item appears in the following Collection(s)

Show simple item record